SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as community members rally around the crypto's connection to cannabis culture and positive vibes, emphasizing it as more than just a digital token. The community highlights a focus on the "culture," which resonates with those who enjoy cannabis. Discussions also involve broader trends in the cannabis industry and the potential impact on crypto.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending as the community debates its future following recent news and financial updates, with discussion focused on potential dilution from share issuance and the company's valuation. Some traders are pointing to a potential short squeeze and upcoming quantum-related events with NVIDIA, while others express skepticism, citing concerns about dilution and long-term viability. The stock is also being discussed in the context of the broader quantum computing sector and its potential for growth.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending as traders assess the likelihood of a government shutdown and its potential impact on markets, with some anticipating a bullish outcome due to delayed economic data releases. Community discussions revolve around potential price movements, with some eyeing specific levels, while others express concerns about high valuations and the sustainability of the current market rally. Broader factors like seasonal patterns and potential shifts in Federal Reserve policy are also being considered.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics is trending following positive Phase 3 trial data for their skin drug, sonelokimab, which is showing promising results in treating hidradenitis suppurativa. Community discussions revolve around the drug's efficacy and safety profile compared to competitors, as well as speculation regarding potential buyout offers and long-term gains. Some traders are concerned about a possible high placebo response and potential profit-taking despite overall optimism for MoonLake's future.

Meet Pandu — your AI friend who’s always by your side. Talk with him in real time through text or voice, share your thoughts, ask questions, or just enjoy a casual conversation. Whether you’re looking for advice, company, or simply someone to listen, Pandu is here as a true companion you can connect with anytime.  Pandu unites real-time conversation, creative generation, and future-ready AI systems — all powered by next-gen technology.

Pandu Pandas

Pandu Pandas ($PANDU.X) is trending, with community members highlighting its recent listing on MEXC and anticipating upcoming announcements from the team. Some users are drawing comparisons to other tokens like $PENGU.X and noting bullish indicators such as its NFT ranking, while others discuss wallet preferences and on-chain fundamentals.

Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg and Hennie Hoogenboom on June 16, 2003 and is headquartered in Utrecht, the Netherlands.

Merus N.V

Merus (MRUS) is trending amid buyout rumors, with Genmab reportedly leading the acquisition race, exciting retail traders. Community chatter highlights the potential deal's price and overall impact, while some regret past decisions to sell shares.  Analysts are also weighing in, adjusting ratings and price targets, contributing to the stock's current momentum.

Aduro Clean Technologies, Inc. engages in the manufacture of oils and specialty chemicals using waste plastics. It focuses on hydrochemolytic technology to transform post-consumer polymer waste into a resource for the circular economy. It also develops a novel chemical conversion process to transform waste plastics and low grade renewable oils into renewable fuels and specialty chemicals. The company was founded on January 10, 2018 by Ofer Vicus and William Marcus Trygstad and is headquartered in Sarnia, Canada.

Aduro Clean Technologies Inc

Aduro Clean Technologies is trending amid discussions about its pilot plant progress and potential partnerships, with the commissioning of the pilot plant scheduled for later this year. The community is weighing in on the company's technology and market position, especially compared to competitors in the recycling space. Some investors are expressing excitement about the clean-tech sector and Aduro's potential within it.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The crypto, crow with knife, $CAW.X, is trending heavily with community members frequently posting "caw caw". The community is excited about the token's multichain functionality, deflationary mechanisms, and partnerships. Momentum appears to be building, with community members expressing strong bullish sentiment.

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.

Avalo Therapeutics Inc

Avalo Therapeutics ($AVTX) is trending due to speculation that positive data from a failed $MLTX trial could indirectly benefit $AVTX. The community is also discussing the high option prices and potential short squeeze. Some traders are looking at $AVTX in sympathy with other low-float biotech stocks that have seen recent gains, while others highlight upcoming investor conferences as potential catalysts.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

DJIA is trending as investors digest economic data and monitor potential shifts in Federal Reserve policy, including possible rate cuts and reactions to inflation. Community members are closely watching developments around tariffs, geopolitical tensions, and potential government interventions. Additionally, there's chatter about individual stock performance within the index and broader market valuations.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is Axsome (AXSM) Up 19.2% Since Last Earnings Report?

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Axsome Shares Up 20% in a Month: How Should You Play the Stock?

AXSM shares rise 20.2% in a month, powered by booming Auvelity sales and a growing CNS drug pipeline.

AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y

Axsome posts narrower second-quarter loss and 72% revenue surge, driven by strong Auvelity sales.

Here's What Key Metrics Tell Us About Axsome (AXSM) Q2 Earnings

While the top- and bottom-line numbers for Axsome (AXSM) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Axsome Therapeutics (AXSM) Reports Q2 Loss, Beats Revenue Estimates

Axsome (AXSM) delivered earnings and revenue surprises of +8.00% and +7.47%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Amgen (AMGN) Reports Next Week: Wall Street Expects Earnings Growth

Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Axsome (AXSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ALKS Down Despite Positive Top-Line Data From Narcolepsy Study

Alkermes falls 8.8% despite alixorexton hitting key goals in a narcolepsy type 1 study, as cataplexy data stirs investor concerns.

Here's Why Harmony Biosciences Is an Unconventional Cannabis Investment

HRMY isn't your typical cannabis play - its synthetic CBD gel targets rare brain disorders with no approved therapies.

Shares of Axsome Therapeutics, Inc. (AXSM) slumped 3% in the pre-market session on Monday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/06/09/3095729/33090/en/Axsome-Therapeutics-Provides-Update-on-the-New-Drug-Application-NDA-for-AXS-14-for-the-Management-of-Fibromyalgia.html">said</a> that it has received a Refusal-to-File (RTF) letter from the U.S. Food and Drug Administration (FDA) regarding its application for a drug approval to treat fibromyalgia.The FDA issues refuse-to-file letters if it identifies deficiencies in a company’s application for drug approval.The agency said that upon preliminary review, it found that the new drug application for AXS-14 was not sufficiently complete to permit a substantive review.The FDA noted that it does not consider the second of the two placebo-controlled trials in the submission to be adequate and well-controlled because its primary endpoint was at eight weeks, and it used a flexible-dose paradigm.The agency, however, opined that the first of the two placebo-controlled trials in the submission, which utilized a 12-week endpoint and a fixed-dose paradigm, is adequate and well-controlled. Both studies yielded positive results. &nbsp;To address the FDA’s feedback, Axsome will conduct an additional controlled trial, utilizing a fixed-dose paradigm and a 12-week primary endpoint. The company anticipates initiating the new trial in the fourth quarter of 2025.CEO Herriot Tabuteau said that the company is “well-positioned” to initiate the new trial.Fibromyalgia is a chronic disorder characterized by widespread pain, fatigue, disturbed sleep, depression, and cognitive impairment. Approximately 17 million Americans, 90% of whom are women, are estimated to suffer from the disorder.On Stocktwits, retail sentiment around Axsome stayed unmoved within the ‘bullish’ territory over the past 24 hours while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:627/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_09_at_8_04_44_AM_png_5593dd0fd5.webp" alt="AXSM's Sentiment Meter and Message Volume as of 8:05 a.m. ET on June 9, 2025 | Source: Stocktwits" width="627" height="63"><figcaption>AXSM's Sentiment Meter and Message Volume as of 8:05 a.m. ET on June 9, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user opined that the possibility for the company achieving profitability by the end of the year is “out the window.”<stembedurl>https://stocktwits.com/GrayCapital/message/617244353</stembedurl>Another user, however, brushed it off as a “small delay.”<stembedurl>https://stocktwits.com/cadbrad1/message/617242242</stembedurl><a href="https://stocktwits.com/symbol/AXSM">AXSM stock</a> has risen by about 28% this year and by about 56% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/dow-futures-edge-higher-ahead-of-us-china-talks/chlEazYRbyd">Dow Futures Edge Higher Ahead Of US-China Talks In London: WBD, Apple, Tesla Among Stocks To Watch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Axsome Therapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Axsome Stock Slips Pre-Market After FDA Issues Refusal-To-File Letter: Retail’s Skeptical On Likelihood Of Year-End Profitability

The regulator said that upon preliminary review, it found that the new drug application for AXS-14 was not sufficiently complete to permit a substantive review.

Equity

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

Current Price	$115.00
Prev Close	$116.01
Open	$116.15
Dividend Yield	0.00%
50-Day Moving Average	$113.28
Beta	0.68
Avg. Volume	575,446.05
PE Ratio	-23.02

52-Week High	$139.13
52-Week Low	$75.56
Market Capitalization	$5.83B
EPS (Annual)	-$5.99
Price to Book	79.60
Revenue Per Employee	$564,704.25
Enterprise Value/EBITDA	N/A

AXSM
Axsome Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AXSM News

AXSM Axsome Therapeutics Inc